Compare Sana Biotechnology Inc (SANA) vs Tyson Foods, Inc. (TSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Tyson Foods, Inc. — how do they compare? Sana Biotechnology Inc trades at $3.17 (market cap $1.03B), while Tyson Foods, Inc. trades at $52.15 (market cap $18.39B). The key difference: Tyson Foods, Inc. is far larger — about 17.9× Sana Biotechnology Inc's market cap, and Tyson Foods, Inc. pays a 3.9% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| SANA | TSN | |
|---|---|---|
Market Cap | $1.03B | $18.39B |
Sector | Health | Consumer Staples |
52-Week High | $5.92 | $68.75 |
52-Week Low | $2.68 | $50.72 |
Enterprise Value | $946.04M | $25.66B |
Dividend Yield | — | 3.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.45, down 10.39% in the past 24 hours, reflecting bearish technical signals and negative profitability. The company reported a net loss of $244.17 million for 2025, with a price-to-book ratio of 6.68. Recent news includes investor conference presentations and a peer-reviewed publication in The New England Journal of Medicine highlighting clinical data.
Despite analyst consensus favoring a 'Buy' rating (81.82% of 11 analysts), the stock faces significant risks from negative cash flows, high losses, and potential fiduciary concerns. Upside hinges on successful clinical developments and improved financial performance, but current fundamentals suggest caution for investors.
Tyson Foods (TSN) trades at $52.28, up 1.67% today, but faces bearish technical signals with the stock trading near key support levels. The company reported mixed quarterly results with two beats and one miss in recent quarters, while maintaining modest profitability with 1.03% net margins. Recent news highlights ongoing fraud investigations and reduced 2026 revenue guidance due to beef segment pressures, creating investor uncertainty despite continued institutional buying interest.
The outlook remains cautious with Wall Street maintaining a $69 price target but technical indicators signaling bearish momentum. Investment opportunity exists in the discounted valuation (P/S 0.33) if operational improvements materialize, though risks include ongoing legal scrutiny, commodity price volatility, and execution challenges in the beef business that could pressure near-term performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Tyson Foods, Inc.
Tyson Foods is the largest U.S. producer of processed chicken and beef. It's also a large producer of processed pork and protein-based products under the brands Jimmy Dean, Hillshire Farm, Ball Park, Sara Lee, Aidells, State Fair, and Raised & Rooted, to name a few. Tyson sells 81% of its products through various U.S. channels, including retailers (47% in fiscal 2021), food service (32%), and other packaged food and industrial companies (10%). In addition, 11% of the company's revenue comes from exports to Canada, Mexico, Brazil, Europe, China, and Japan.
Read more on TSN →
